Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Hold” by Brokerages

Shares of Replimune Group, Inc. (NASDAQ:REPL) have been given a consensus rating of “Hold” by the ten analysts that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $9.8750.

A number of research firms have commented on REPL. Wedbush boosted their price target on shares of Replimune Group from $18.00 to $19.00 and gave the company an “outperform” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th. JPMorgan Chase & Co. upgraded Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a research report on Monday, October 20th. Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective on the stock in a research note on Monday, October 20th. Finally, Leerink Partners upgraded Replimune Group from a “market perform” rating to an “outperform” rating and increased their target price for the stock from $3.00 to $13.00 in a report on Monday, October 20th.

Replimune Group Stock Performance

Shares of NASDAQ:REPL opened at $7.00 on Thursday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The business’s fifty day moving average price is $8.88 and its two-hundred day moving average price is $7.22. Replimune Group has a fifty-two week low of $2.68 and a fifty-two week high of $14.80. The stock has a market capitalization of $549.08 million, a price-to-earnings ratio of -2.03 and a beta of 0.73.

Replimune Group (NASDAQ:REPL) last issued its earnings results on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, beating the consensus estimate of ($0.85) by $0.08. As a group, analysts predict that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In related news, Director Kapil Dhingra sold 3,169 shares of the firm’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total value of $32,957.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the transaction, the chief executive officer owned 333,576 shares of the company’s stock, valued at $3,712,700.88. This trade represents a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 25,625 shares of company stock worth $257,607. 5.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Replimune Group

Several large investors have recently made changes to their positions in the company. Readystate Asset Management LP raised its position in shares of Replimune Group by 1,296.2% during the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after acquiring an additional 2,433,292 shares during the last quarter. Braidwell LP boosted its holdings in Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after buying an additional 2,327,205 shares during the last quarter. Balyasny Asset Management L.P. grew its position in shares of Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after buying an additional 2,195,448 shares during the period. Erste Asset Management GmbH raised its position in shares of Replimune Group by 13,597.5% in the 3rd quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock valued at $7,074,000 after acquiring an additional 1,618,100 shares during the period. Finally, UBS Group AG boosted its stake in Replimune Group by 270.4% during the 3rd quarter. UBS Group AG now owns 901,630 shares of the company’s stock worth $3,778,000 after acquiring an additional 658,233 shares during the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.